Jubilant Pharmova Limited (JUBLPHARMA.BO)
INR 902.0
(1.33%)
INR 902.0
(1.33%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 36.64 Billion INR | -0.35% |
| 2022 | 36.76 Billion INR | 15.19% |
| 2021 | 31.92 Billion INR | 12.81% |
| 2020 | 28.29 Billion INR | -41.15% |
| 2019 | 48.08 Billion INR | -0.66% |
| 2018 | 48.4 Billion INR | 39.54% |
| 2017 | 34.68 Billion INR | -14.25% |
| 2016 | 40.45 Billion INR | -9.97% |
| 2015 | 44.93 Billion INR | -6.33% |
| 2014 | 47.96 Billion INR | 9.13% |
| 2013 | 43.95 Billion INR | 3.54% |
| 2012 | 42.45 Billion INR | 11.16% |
| 2011 | 38.18 Billion INR | 2.67% |
| 2010 | 37.19 Billion INR | 17.23% |
| 2009 | 31.72 Billion INR | -19.51% |
| 2008 | 39.41 Billion INR | 86.95% |
| 2007 | 21.08 Billion INR | 27.58% |
| 2006 | 16.52 Billion INR | 128.88% |
| 2005 | 7.22 Billion INR | 94.16% |
| 2004 | 3.71 Billion INR | -11.67% |
| 2003 | 4.21 Billion INR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 28.25 Billion INR | 0.0% |
| 2024 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 36.64 Billion INR | 0.0% |
| 2023 Q2 | 36.67 Billion INR | 0.0% |
| 2023 FY | 36.64 Billion INR | -0.35% |
| 2022 Q2 | 34.96 Billion INR | 0.0% |
| 2022 Q4 | 36.76 Billion INR | 0.0% |
| 2022 FY | 36.76 Billion INR | 15.19% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 29.51 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 31.92 Billion INR | 0.0% |
| 2021 FY | 31.92 Billion INR | 12.81% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 28.29 Billion INR | -41.15% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 28.29 Billion INR | 0.0% |
| 2020 Q2 | 39.99 Billion INR | 0.0% |
| 2019 Q2 | 44.87 Billion INR | 0.0% |
| 2019 FY | 48.08 Billion INR | -0.66% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q4 | 48.08 Billion INR | 0.0% |
| 2018 FY | 48.4 Billion INR | 39.54% |
| 2018 Q4 | 48.4 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 38.49 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2017 FY | 34.68 Billion INR | -14.25% |
| 2017 Q2 | 35.94 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q4 | 34.68 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 FY | 40.45 Billion INR | -9.97% |
| 2016 Q2 | 37.04 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q4 | 40.45 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 FY | 44.93 Billion INR | -6.33% |
| 2015 Q4 | 44.93 Billion INR | 0.0% |
| 2015 Q2 | 35.36 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2014 Q4 | 47.96 Billion INR | 0.0% |
| 2014 FY | 47.96 Billion INR | 9.13% |
| 2014 Q2 | 38.27 Billion INR | 0.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 Q3 | - INR | -100.0% |
| 2013 Q4 | 43.95 Billion INR | 0.0% |
| 2013 FY | 43.95 Billion INR | 3.54% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 28.27 Billion INR | 0.0% |
| 2012 Q4 | 42.45 Billion INR | 0.0% |
| 2012 FY | 42.45 Billion INR | 11.16% |
| 2011 FY | 38.18 Billion INR | 2.67% |
| 2011 Q4 | 38.18 Billion INR | 0.0% |
| 2010 FY | 37.19 Billion INR | 17.23% |
| 2009 FY | 31.72 Billion INR | -19.51% |
| 2008 FY | 39.41 Billion INR | 86.95% |
| 2007 FY | 21.08 Billion INR | 27.58% |
| 2006 FY | 16.52 Billion INR | 128.88% |
| 2005 FY | 7.22 Billion INR | 94.16% |
| 2004 FY | 3.71 Billion INR | -11.67% |
| 2003 FY | 4.21 Billion INR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Bajaj HealthCare Limited | 3.32 Billion INR | -1000.881% |
| Aarti Drugs Limited | 5.64 Billion INR | -549.335% |
| NATCO Pharma Limited | 3.71 Billion INR | -887.069% |
| Aarti Pharmalabs Limited | 2.85 Billion INR | -1184.487% |
| RPG Life Sciences Limited | - INR | -Infinity% |
| Shilpa Medicare Limited | 9.37 Billion INR | -290.873% |
| Suven Pharmaceuticals Limited | 649.96 Million INR | -5537.235% |
| Alkem Laboratories Limited | 14.18 Billion INR | -158.317% |
| Torrent Pharmaceuticals Limited | 40.22 Billion INR | 8.901% |
| Venus Remedies Limited | 413.3 Million INR | -8765.231% |
| Lasa Supergenerics Limited | 220.76 Million INR | -16497.059% |
| Ind-Swift Limited | 10.13 Billion INR | -261.343% |
| Hester Biosciences Limited | 2.44 Billion INR | -1399.317% |
| Indoco Remedies Limited | 6.71 Billion INR | -445.271% |
| Bal Pharma Limited | 1.39 Billion INR | -2523.732% |
| Hikal Limited | 8.17 Billion INR | -348.152% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Ind-Swift Laboratories Limited | 166.21 Million INR | -21943.606% |
| Ajanta Pharma Limited | 352.8 Million INR | -10285.488% |
| Alpa Laboratories Limited | 52.46 Million INR | -69737.034% |
| AstraZeneca Pharma India Limited | 45.98 Million INR | -79583.354% |
| Aurobindo Pharma Limited | 66.47 Billion INR | 44.883% |
| Biofil Chemicals and Pharmaceuticals Limited | 4.38 Million INR | -834714.308% |
| Brooks Laboratories Limited | 56.41 Million INR | -64842.661% |
| Nectar Lifesciences Limited | 6.35 Billion INR | -476.521% |
| Divi's Laboratories Limited | 30 Million INR | -122033.333% |
| Dr. Reddy's Laboratories Limited | 20.02 Billion INR | -83.017% |
| Eris Lifesciences Limited | 27.81 Billion INR | -31.738% |
| Glenmark Pharmaceuticals Limited | 12.3 Billion INR | -197.661% |
| Glenmark Life Sciences Limited | 171.48 Million INR | -21266.923% |
| Granules India Limited | 13.15 Billion INR | -178.618% |
| Gufic Biosciences Limited | 3.32 Billion INR | -1000.579% |
| IOL Chemicals and Pharmaceuticals Limited | 327.6 Million INR | -11084.371% |
| Ipca Laboratories Limited | 14.38 Billion INR | -154.735% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | -1794.23% |
| Laurus Labs Limited | 25.77 Billion INR | -42.159% |
| Mankind Pharma Limited | 2.07 Billion INR | -1668.575% |
| Medicamen Biotech Limited | 308.17 Million INR | -11789.464% |
| Medico Remedies Limited | 80.5 Million INR | -45413.266% |
| Megasoft Limited | 1.47 Billion INR | -2391.72% |
| Procter & Gamble Health Limited | 95.6 Million INR | -38226.36% |
| Piramal Pharma Limited | 47.1 Billion INR | 22.211% |
| Sequent Scientific Limited | 4.87 Billion INR | -651.292% |
| Sigachi Industries Limited | 1.43 Billion INR | -2461.312% |
| Solara Active Pharma Sciences Limited | 10.11 Billion INR | -262.234% |
| Strides Pharma Science Limited | 25.16 Billion INR | -45.578% |
| Sun Pharmaceutical Industries Limited | 32.73 Billion INR | -11.923% |
| Themis Medicare Limited | 957.92 Million INR | -3724.946% |
| Unichem Laboratories Limited | 2.47 Billion INR | -1380.319% |
| Wanbury Limited | 1.16 Billion INR | -3045.48% |
| Windlas Biotech Limited | 36.41 Million INR | -100531.695% |
| Wockhardt Limited | 23.56 Billion INR | -55.518% |
| ZIM Laboratories Limited | 1.08 Billion INR | -3266.892% |
| Bliss GVS Pharma Limited | 998.4 Million INR | -3569.868% |
| Suven Life Sciences Limited | 7.09 Million INR | -516174.482% |
| Amrutanjan Health Care Limited | 17.28 Million INR | -211900.231% |
| Alembic Pharmaceuticals Limited | 5.13 Billion INR | -614.007% |
| Lupin Limited | 29.21 Billion INR | -25.403% |
| Sun Pharma Advanced Research Company Limited | 611.5 Million INR | -5891.823% |
| Syncom Formulations (India) Limited | 724.86 Million INR | -4954.727% |
| Valiant Laboratories Limited | 767.08 Million INR | -4676.53% |
| Zydus Lifesciences Limited | 8.04 Billion INR | -355.608% |
| FDC Limited | 205.18 Million INR | -17757.056% |
| J. B. Chemicals & Pharmaceuticals Limited | 3.77 Billion INR | -870.185% |
| Novartis India Limited | 69.7 Million INR | -52468.149% |
| Jagsonpal Pharmaceuticals Limited | 89.41 Million INR | -40879.756% |
| Neuland Laboratories Limited | 953.89 Million INR | -3741.09% |
| Morepen Laboratories Limited | 289.99 Million INR | -12534.831% |
| Kilitch Drugs (India) Limited | 316.46 Million INR | -11477.9% |
| Mangalam Drugs & Organics Limited | 984.92 Million INR | -3620.08% |